INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 433m ago
HOUSE PTR32m ago
SEC 13F32m ago
ROBINHOOD CHAIN32m ago
SEC FORM 4/Option exerciseVerified dataRule 10b5-1 plan

Anderson Raymond reported MNPR

Director · Monopar Therapeutics · Monopar Therapeutics — Stock Option

Side
M
Value
—
Shares
1,740
Price
—
Executed
Nov 2, 2026
Disclosed
Nov 4, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Nov 2 executedNov 4, 2026 disclosed

MNPR · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
0/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · MNPR

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    7
    AR
    Anderson RaymondDirector
    MNPRMonopar Therapeutics
    Option exercise · 10b5-1 plan
    		M$42K
    1,402 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    10
    AR
    Anderson RaymondDirector
    MNPRMonopar Therapeutics
    Option exercise · 10b5-1 plan
    		M$52K
    1,740 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    25
    TR
    Tsuchimoto Kim RDirector
    MNPRMonopar Therapeutics
    Open-market sale · 10b5-1 plan
    		SELL$84K
    1,199 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    0
    TR
    Tsuchimoto Kim RDirector
    MNPRMonopar Therapeutics
    Option exercise · 10b5-1 plan
    		M$26K
    856 sh
    		Nov 4, 2026Nov 4, 2026
    traded Nov 4, 2026
    		+0dSEC FORM 4

    Evidence

    7
    TR
    Tsuchimoto Kim RDirector
    MNPRMonopar Therapeutics
    Option exercise · 10b5-1 plan
    		M$28K
    2,035 sh
    		Nov 4, 2026Nov 4, 2026
    traded Nov 4, 2026
    		+0dSEC FORM 4

    Evidence

    17
    TR
    Tsuchimoto Kim RDirector
    MNPRMonopar Therapeutics
    Open-market sale · 10b5-1 plan
    		SELL$92K
    1,295 sh
    		Nov 4, 2026Nov 4, 2026
    traded Nov 4, 2026
    		+0dSEC FORM 4

    Evidence

    21
    TR
    Tsuchimoto Kim RDirector
    MNPRMonopar Therapeutics
    Open-market sale · 10b5-1 plan
    		SELL$71K
    996 sh
    		Nov 4, 2026Nov 4, 2026
    traded Nov 4, 2026
    		+0dSEC FORM 4

    Evidence

    10
    AR
    Anderson RaymondDirector
    MNPRMonopar Therapeutics
    Open-market sale · 10b5-1 plan
    		SELL$14K
    200 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    21
    AR
    Anderson RaymondDirector
    MNPRMonopar Therapeutics
    Open-market sale · 10b5-1 plan
    		SELL$105K
    1,502 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    0
    AR
    Anderson RaymondDirector
    MNPRMonopar Therapeutics
    Option exercise · 10b5-1 plan
    		M—
    1,402 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    0
    TR
    Tsuchimoto Kim RDirector
    MNPRMonopar Therapeutics
    Option exercise · 10b5-1 plan
    		M$36K
    1,199 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    7
    TR
    Tsuchimoto Kim RDirector
    MNPRMonopar Therapeutics
    Option exercise · 10b5-1 plan
    		M—
    1,199 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    3
    TR
    Tsuchimoto Kim RDirector
    MNPRMonopar Therapeutics
    Option exercise · 10b5-1 plan
    		M—
    856 sh
    		Nov 4, 2026Nov 4, 2026
    traded Nov 4, 2026
    		+0dSEC FORM 4

    Evidence

    7
    TR
    Tsuchimoto Kim RDirector
    MNPRMonopar Therapeutics
    Option exercise · 10b5-1 plan
    		M—
    2,035 sh
    		Nov 4, 2026Nov 4, 2026
    traded Nov 4, 2026
    		+0dSEC FORM 4

    Evidence

    17
    AR
    Anderson RaymondDirector
    MNPRMonopar Therapeutics
    Open-market sale · 10b5-1 plan
    		SELL$56K
    840 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    14
    AR
    Anderson RaymondDirector
    MNPRMonopar Therapeutics
    Open-market sale · 10b5-1 plan
    		SELL$40K
    600 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    18
    TR
    Tsuchimoto Kim RDirector
    MNPRMonopar Therapeutics
    Open-market sale · 10b5-1 plan
    		SELL$43K
    600 sh
    		Nov 4, 2026Nov 4, 2026
    traded Nov 4, 2026
    		+0dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001437749-26-035040
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Nov 2, 2026
    Published
    Nov 4, 2026
    Ingested by INSIDER
    Nov 5, 02:12 UTC
    Last re-read
    Nov 5, 15:28 UTC

    Extracted facts

    Filer
    Anderson Raymond
    Role
    Director
    Transaction
    Option exerciseAs filed: “M”
    Asset
    Monopar Therapeutics — Stock Option
    Ticker
    MNPR
    Shares
    1,740
    Price per share
    $0
    Execution date (reported)
    Nov 2, 2026
    Owned after transaction
    1,740 shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    2

    What this establishes

    Anderson Raymond filed this Form 4 reporting a option exercise of MNPR on Nov 2, 2026. It became public on Nov 4, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Anderson Raymondcik:0001362489
    Issuer
    Monopar Therapeuticscik:0001645469

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.